Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Advanced Breast Cancer
NEW YORK, Dec. 8, 2021 -- (Healthcare Sales & Marketing Network) -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today anno... Biopharmaceuticals, Oncology, FDA Nuvation Bio , breast cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Investigational New Drugs | Marketing | New Drug Applications | Pharmaceuticals